USPTO Approves Two PetVivo Patent Applications for Allowance
Petvivo Holdings Inc (OTCMKTS:PETV)
MINNEAPOLIS, MN, US, March 19, 2018 /EINPresswire.com/ — PetVivo Holdings, Inc. (www.petvivo.com) (OTCMARKET:PETV), parent company of Gel-Del Technologies, Inc., has recently been approved by the U.S. Patent and Trademark Office (USPTO) for the grant of two patents directed to the company’s signature products: protein-based biomaterials used for various beneficial medical applications, including drug delivery devices, coated medical devices (e.g., stents and valves), and tubular/vascular grafts. Craige Thompson, PetVivo’s Patent Counsel, has expressed that he is “quite pleased with the outcome of patent prosecution at the USPTO. It is great news that the Patent Office has recognized the patentability of these revolutionary inventions.
The first patent application pending grant by the USPTO is U.S. Pat. App. Ser. No. 14/827,513 titled “Protein Biomaterials and Biocoacervates and Methods of Making and Using Thereof.” The allowed claims of this patent application are generally directed to “amorphous biocoacervate material[s] that [are] crosslinked with one or more crosslinking agents.” The below figure illustrates “one embodiment of the particles of the present invention [in which] a slurry of particles and saline are delivered through a 27-gauge needle.”
The second patent application pending grant by the USPTO is U.S. Pat. App. Ser. No. 13/131,083 titled “Protein Biomaterial and Biocoacervate Vessel Graft Systems and Methods of Making and Using Thereof.” The allowed claims of this patent application are generally directed to a “vessel graft system comprising: one or more tube(s) including… a first biomaterial formed from one or more precipitated amorphous thermoplastic biocoacervate(s).” The below figure illustrates a “vessel graft including a… mesh tube… [where a] melted biocoacervate may be applied to the scaffolding structure”
“The company’s move to use Thompson Patent Law firm late last year has proven to be one of our best decisions. In addition to the two patent allowances, we have additional patents pending. These patents are in line with future products as the Company moves forward.” Stated Wes Hayne, CEO of PetVivo Holdings, Inc.
About PetVivo Holdings, Inc.
PetVivo Holdings Inc. (OTCPINK: PETV) is an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices for pets and pet therapeutics. PetVivo is leveraging investments made in the human medical device industry to commercialize therapeutics for pets in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than the more stringently regulated pharmaceuticals.
PetVivo’s strategy is to commercialize proprietary products from human medical device companies specifically for the companion animal market. The company’s product pipeline includes seventeen animal and human therapeutics. A portfolio of twenty patents protects the company’s products, production processes and biomaterials. PetVivo’s lead product, a veterinarian-administered joint injection for the treatment of osteoarthritis in dogs, is scheduled for launch later this year.
The Company will also be seeking licensing partners to commercialize its portfolio of proprietary human clinical therapeutics in large market sectors, including: cardiovascular, orthopedic, urology and aesthetics.
Forward-Looking commercial Statements:
The foregoing material may contain forward-looking statements. We caution that such statements may be subject to uncertainties and that actual results could differ materially from the forward-looking statements. Readers accordingly should not place undue reliance on these forward-looking statements, which do not reflect unknown or unanticipated events or circumstances occurring after the date of these forward-looking statements.
PetVivo Holdings, Inc.
Direct: (763) 443-7272
Petvivo Holdings Inc
email us here